HRP20201311T1 - Prohemostatski proteini za liječenje krvarenja - Google Patents
Prohemostatski proteini za liječenje krvarenja Download PDFInfo
- Publication number
- HRP20201311T1 HRP20201311T1 HRP20201311TT HRP20201311T HRP20201311T1 HR P20201311 T1 HRP20201311 T1 HR P20201311T1 HR P20201311T T HRP20201311T T HR P20201311TT HR P20201311 T HRP20201311 T HR P20201311T HR P20201311 T1 HRP20201311 T1 HR P20201311T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- seq
- acid residues
- protein according
- protein
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims 12
- 102000004169 proteins and genes Human genes 0.000 title claims 12
- 208000032843 Hemorrhage Diseases 0.000 title 1
- 208000034158 bleeding Diseases 0.000 title 1
- 230000000740 bleeding effect Effects 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 claims 10
- 238000003780 insertion Methods 0.000 claims 5
- 230000037431 insertion Effects 0.000 claims 5
- 229940123688 Direct Factor Xa inhibitor Drugs 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims 2
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 claims 2
- 108010074860 Factor Xa Proteins 0.000 claims 2
- XHOLNRLADUSQLD-UHFFFAOYSA-N betrixaban Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 XHOLNRLADUSQLD-UHFFFAOYSA-N 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000002429 anti-coagulating effect Effects 0.000 claims 1
- 229960003886 apixaban Drugs 0.000 claims 1
- 229950011103 betrixaban Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960000622 edoxaban Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960001148 rivaroxaban Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (13)
1. Rekombinantni protein koji sadrži koagulacijski faktor Xa polipeptid sisavca, navedeni polipeptid ima promjenu u području amino-kiselinskih ostataka koji odgovara području između Gly-289 i Asp-320, poželjno između His-311 i Asp-320 SEQ ID NO: 1; naznačeno time što je navedena promjena umetanja 1-50 amino-kiselinskih ostataka, i pri čemu navedeni promijenjeni protein ima smanjenu osjetljivost na inhibiciju od strane direktnog inhibitora faktora Xa kada se usporedi sa navedenim koagulacijskim faktorom Xa polipeptidom sisavca koji nema navedenu promjenu.
2. Protein u skladu sa patentnim zahtjevom 1, naznačen time što je umetanje 1-20 amino-kiselinskih ostataka.
3. Protein u skladu sa bilo kojim od patentnih zahtjeva 1-2, naznačen time što je navedeno umetanje između dva amino-kiselinska ostatka koja odgovaraju Lys-316 i Glu-317 SEQ ID NO: 1.
4. Protein u skladu sa bilo kojim od patentnih zahtjeva 1-3, naznačen time što je umetanje najmanje jednog amino-kiselinskog ostatka kombinirana sa zamjenom između 1-8 amino-kiselinskih ostataka u području amino-kiselinskih ostataka između Gly-289 i Asp-320, poželjno između His-311 i Asp-320 SEQ ID NO: 1.
5. Protein u skladu sa bilo kojim od patentnih zahtjeva 1-4, naznačen time što je navedeno umetanje 9-13 amino-kiselinskih ostataka.
6. Protein u skladu sa bilo kojim od patentnih zahtjeva 1-5, naznačen time što područje amino-kiselinskih ostataka koje odgovara području amino-kiselinskih ostataka između His-311 i Asp-320 SEQ ID NO: 1 ima amino-kiselinsku sekvencu SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 10, ili SEQ ID NO: 11.
7. Molekula nukleinske kiseline koja sadrži DNK sekvencu koja kodira protein u skladu sa bilo kojim od patentnih zahtjeva 1-6.
8. Ekspresijski vektor koji sadrži molekulu nukleinske kiseline u skladu sa patentnim zahtjevom 7.
9. Stanica domaćina koja sadrži molekulu nukleinske kiseline u skladu sa patentnim zahtjevom 7 ili ekspresijski vektor u skladu sa patentnim zahtjevom 8.
10. Farmaceutski pripravak koji sadrži protein u skladu sa bilo kojim od patentnih zahtjeva 1-6, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv nosač.
11. Protein u skladu sa bilo kojim od patentnih zahtjeva 1-6, ili farmaceutski pripravak u skladu sa patentnim zahtjevom 10, za upotrebu kao lijek.
12. Protein u skladu sa bilo kojim od patentnih zahtjeva 1-6, ili farmaceutski pripravak u skladu sa patentnim zahtjevom 10 za upotrebu u postupku potpunog ili djelomičnog poništavanja antikoagulantnog efekta direktnog inhibitora faktora Xa kod subjekta.
13. Protein za upotrebu u skladu sa patentnim zahtjevom 12, naznačen time što je direktni inhibitor faktora Xa poželjno rivaroksaban (5-kloro-N-[[(5S)-2-okso-3-[4-(3-okso-4-morfolinil)fenil]-5-oksazolidinil]metil]-2-tiofenkarboksamid), apiksaban (1-(4metoksifenil)-7-okso-6-[4-(2-oksopiperidin-1-il)fenil]-4,5,6,7-tetrahidro-1H-pirazolo [3,4-c]piridin-3-karboksamid), edoksaban (N'-(5-hloropiridin-2-il)-N-[(1S,2R,4S)-4-(dimetilkarbamoil)-2-[(5-metil-6,7-dihidro-4H-[1,3]tiazolo[5,4-c]piridin-2-karbonil) amino]cikloheksil]oksamid;4-metilbenzensulfonska kiselina), ili betriksaban (N-(5-kloropiridin-2-il)-2-[[4-(N,N-dimetilkarbamimidoil)benzoil]amino]-5-metoksibenzamid).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14169895 | 2014-05-26 | ||
| EP15731411.3A EP3149163B1 (en) | 2014-05-26 | 2015-05-26 | Prohemostatic proteins for the treatment of bleeding |
| PCT/NL2015/050377 WO2015183085A1 (en) | 2014-05-26 | 2015-05-26 | Prohemostatic proteins for the treatment of bleeding |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201311T1 true HRP20201311T1 (hr) | 2020-12-11 |
Family
ID=50774744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201311TT HRP20201311T1 (hr) | 2014-05-26 | 2020-08-21 | Prohemostatski proteini za liječenje krvarenja |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10537618B2 (hr) |
| EP (2) | EP3149163B1 (hr) |
| JP (3) | JP6640198B2 (hr) |
| KR (2) | KR102351728B1 (hr) |
| CN (1) | CN106536566A (hr) |
| AU (2) | AU2015268149B2 (hr) |
| BR (1) | BR112016027649A2 (hr) |
| CA (1) | CA2949349A1 (hr) |
| DK (1) | DK3149163T3 (hr) |
| EA (2) | EA202190813A1 (hr) |
| ES (1) | ES2813440T3 (hr) |
| HR (1) | HRP20201311T1 (hr) |
| HU (1) | HUE052098T2 (hr) |
| IL (2) | IL249132B (hr) |
| LT (1) | LT3149163T (hr) |
| MA (2) | MA51688A (hr) |
| MX (2) | MX2016015567A (hr) |
| NZ (1) | NZ727444A (hr) |
| PL (1) | PL3149163T3 (hr) |
| PT (1) | PT3149163T (hr) |
| RS (1) | RS60706B1 (hr) |
| SG (2) | SG11201609811TA (hr) |
| SI (1) | SI3149163T1 (hr) |
| WO (1) | WO2015183085A1 (hr) |
| ZA (1) | ZA201608017B (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106536566A (zh) | 2014-05-26 | 2017-03-22 | 莱顿教学医院 | 用于出血治疗的促止血蛋白 |
| CN108486197B (zh) * | 2018-03-06 | 2021-10-22 | 爱斯特（成都）生物制药股份有限公司 | 高纯度依度沙班中间体的制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| DK0574402T3 (da) | 1990-11-26 | 1998-05-18 | Chiron Corp | Ekspression af PACE i værtsceller og fremgangsmåder til anvendelse deraf |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| DE4203965A1 (de) | 1992-02-11 | 1993-08-12 | Max Planck Gesellschaft | Antidot fuer hirudin und synthetische thrombininhibitoren |
| AT404357B (de) | 1995-06-13 | 1998-11-25 | Immuno Ag | Prothrombin-derivate |
| DE19605126A1 (de) | 1996-02-12 | 1997-08-14 | Basf Ag | Thrombinmuteine als Antidot für Thrombininhibitoren |
| US6200955B1 (en) | 1996-06-11 | 2001-03-13 | Commonwealth Biotechnologies, Inc. | Heparin binding peptides |
| US6624141B1 (en) | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
| EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| MX336958B (es) * | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| EP1820508A1 (en) * | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| EP2147096B1 (en) * | 2007-04-13 | 2015-03-25 | Catalyst Biosciences, Inc. | Modified factor VII polypeptides and uses thereof |
| DK3078743T3 (da) | 2007-09-28 | 2020-08-10 | Portola Pharm Inc | Antidoter til faktor xa-inhibitorer og fremgangsmåder til anvendelse af disse |
| TWI538916B (zh) * | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
| CN102625712B (zh) | 2009-07-15 | 2017-07-25 | 博尔托拉制药公司 | 用于因子xa抑制剂的解毒剂的单位剂量制剂及其使用方法 |
| ES2704083T3 (es) | 2012-07-25 | 2019-03-14 | Catalyst Biosciences Inc | Polipéptidos de factor x modificados y usos de los mismos |
| US20150343034A1 (en) | 2013-01-31 | 2015-12-03 | Pfizer Inc. | Compositions and methods for counteracting factor xa inhibition |
| US10119101B2 (en) | 2014-04-28 | 2018-11-06 | Ecolab Usa Inc. | Method of minimizing enzyme based aerosol mist using a pressure spray system |
| CN106536566A (zh) * | 2014-05-26 | 2017-03-22 | 莱顿教学医院 | 用于出血治疗的促止血蛋白 |
-
2015
- 2015-05-26 CN CN201580039023.6A patent/CN106536566A/zh active Pending
- 2015-05-26 KR KR1020217011631A patent/KR102351728B1/ko active IP Right Grant
- 2015-05-26 HU HUE15731411A patent/HUE052098T2/hu unknown
- 2015-05-26 RS RS20200990A patent/RS60706B1/sr unknown
- 2015-05-26 SI SI201531321T patent/SI3149163T1/sl unknown
- 2015-05-26 SG SG11201609811TA patent/SG11201609811TA/en unknown
- 2015-05-26 PL PL15731411T patent/PL3149163T3/pl unknown
- 2015-05-26 AU AU2015268149A patent/AU2015268149B2/en active Active
- 2015-05-26 EA EA202190813A patent/EA202190813A1/ru unknown
- 2015-05-26 US US15/313,881 patent/US10537618B2/en active Active
- 2015-05-26 MA MA051688A patent/MA51688A/fr unknown
- 2015-05-26 MA MA40042A patent/MA40042B1/fr unknown
- 2015-05-26 BR BR112016027649A patent/BR112016027649A2/pt active Search and Examination
- 2015-05-26 CA CA2949349A patent/CA2949349A1/en active Pending
- 2015-05-26 NZ NZ727444A patent/NZ727444A/en unknown
- 2015-05-26 WO PCT/NL2015/050377 patent/WO2015183085A1/en active Application Filing
- 2015-05-26 EP EP15731411.3A patent/EP3149163B1/en active Active
- 2015-05-26 ES ES15731411T patent/ES2813440T3/es active Active
- 2015-05-26 LT LTEP15731411.3T patent/LT3149163T/lt unknown
- 2015-05-26 DK DK15731411.3T patent/DK3149163T3/da active
- 2015-05-26 JP JP2017515659A patent/JP6640198B2/ja active Active
- 2015-05-26 SG SG10201906329VA patent/SG10201906329VA/en unknown
- 2015-05-26 KR KR1020167033773A patent/KR102245264B1/ko active IP Right Grant
- 2015-05-26 EP EP20177786.9A patent/EP3744840A1/en active Pending
- 2015-05-26 PT PT157314113T patent/PT3149163T/pt unknown
- 2015-05-26 MX MX2016015567A patent/MX2016015567A/es unknown
- 2015-05-26 EA EA201692161A patent/EA037991B1/ru unknown
-
2016
- 2016-11-18 ZA ZA2016/08017A patent/ZA201608017B/en unknown
- 2016-11-22 IL IL249132A patent/IL249132B/en active IP Right Grant
- 2016-11-25 MX MX2020013410A patent/MX2020013410A/es unknown
-
2019
- 2019-12-18 US US16/719,875 patent/US11304995B2/en active Active
- 2019-12-18 US US16/719,866 patent/US11357836B2/en active Active
- 2019-12-25 JP JP2019235197A patent/JP2020062039A/ja active Pending
-
2020
- 2020-08-21 HR HRP20201311TT patent/HRP20201311T1/hr unknown
- 2020-09-15 IL IL277377A patent/IL277377B/en unknown
-
2021
- 2021-06-10 AU AU2021203838A patent/AU2021203838B2/en active Active
-
2022
- 2022-05-31 US US17/829,180 patent/US20220288172A1/en active Pending
- 2022-06-24 JP JP2022102258A patent/JP2022134139A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201311T1 (hr) | Prohemostatski proteini za liječenje krvarenja | |
| CA2573219C (en) | Hepatitis c inhibitor dipeptide analogs | |
| ES2629414T3 (es) | Derivados de tiazol | |
| TWI530286B (zh) | 作為抑制病毒化合物之抗發炎劑 | |
| ES2661500T3 (es) | Variantes de HMGB1 y sus usos | |
| IL269293A (en) | Dual-suitable molten compounds 6-6 Troaril and their use as LATS inhibitors | |
| PE20120119A1 (es) | AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 | |
| JP2018506286A5 (hr) | ||
| EA201990900A1 (ru) | Стабильный при комнатной температуре лиофилизированный белок | |
| JP2018510622A5 (hr) | ||
| EA201270322A1 (ru) | НОВЫЙ ЭНДОЛИЗИН OBPgpLYS | |
| PE20161441A1 (es) | Compuesto de ciclopropanamina y sus usos | |
| JP2016520320A5 (hr) | ||
| JP2012115277A5 (hr) | ||
| JP2015510393A5 (hr) | ||
| PE20170186A1 (es) | Nuevos compuestos | |
| EA201991409A2 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| FI3526323T3 (fi) | Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja | |
| JP2018531624A5 (hr) | ||
| PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina | |
| RU2015112625A (ru) | Пептид, применение пептида для лечения сердечно-сосудистых заболеваний, нуклеотидная последовательность, вектор экспрессии, хозяйская клетка, фармацевтическая композиция | |
| JP2014529399A5 (hr) | ||
| SI2718434T1 (en) | Compounds and procedures for the treatment of celiac disease | |
| EA201891141A1 (ru) | Новые антиангиогенные слитые полипептиды | |
| RU2017114673A (ru) | Слитый белок, наночастица, состоящая из множества мономеров указанного слитого белка, и их применение |